Sanford C. Bernstein Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $310.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by Sanford C. Bernstein from $314.00 to $310.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other analysts have also commented on the company. Chardan Capital reissued a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $298.61.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $240.55 on Tuesday. The stock has a market cap of $31.03 billion, a PE ratio of -91.81 and a beta of 0.34. The firm has a 50-day moving average of $249.60 and a 200-day moving average of $259.41. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period last year, the firm posted $1.15 EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -2.21 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the transaction, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at $3,941,955. The trade was a 10.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,122 shares of company stock worth $2,540,455 in the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Los Angeles Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at $578,000. Toronto Dominion Bank raised its stake in Alnylam Pharmaceuticals by 27.3% during the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock valued at $4,254,000 after purchasing an additional 3,315 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in Alnylam Pharmaceuticals by 22.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock valued at $20,165,000 after purchasing an additional 13,422 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $7,009,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.